1zxv: Difference between revisions

Line 4:

==Overview==

Inhalation anthrax is a deadly disease for which there is currently no, effective treatment. Bacillus anthracis lethal factor (LF), metalloproteinase is an integral component of the tripartite anthrax, lethal toxin that is essential for the onset and progression of anthrax., We report here on a fragment-based approach that allowed us to develop, inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both, in vitro tests and cell-based assays. These inhibitors do not affect the, prototype human metalloproteinases that are structurally similar to LF., Initial in vivo evaluation of postexposure efficacy of our inhibitors, combined with antibiotic ciprofloxacin against B. anthracis resulted in, significant protection. Our data strongly indicate that the scaffold of, inhibitors we have identified is the foundation for the development of, novel, safe, and effective emergency therapy of postexposure inhalation, anthrax.

Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxacin against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.

==About this Structure==

Line 14:

[[Category: Bacillus anthracis]]

[[Category: Single protein]]

[[Category: Liddington, R.C.]]

[[Category: Liddington, R C.]]

[[Category: Wong, T.Y.]]

[[Category: Wong, T Y.]]

[[Category: MFM]]

[[Category: ZN]]

Line 22:

[[Category: zinc metalloproteinase]]

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Tue Jan 29 17~~:45:15 2008''

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:20:07 2008''

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 4: / Line 4: @@
 ==Overview==
-Inhalation anthrax is a deadly disease for which there is currently no, effective treatment. Bacillus anthracis lethal factor (LF), metalloproteinase is an integral component of the tripartite anthrax, lethal toxin that is essential for the onset and progression of anthrax., We report here on a fragment-based approach that allowed us to develop, inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both, in vitro tests and cell-based assays. These inhibitors do not affect the, prototype human metalloproteinases that are structurally similar to LF., Initial in vivo evaluation of postexposure efficacy of our inhibitors, combined with antibiotic ciprofloxacin against B. anthracis resulted in, significant protection. Our data strongly indicate that the scaffold of, inhibitors we have identified is the foundation for the development of, novel, safe, and effective emergency therapy of postexposure inhalation, anthrax.
+Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxacin against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.
 ==About this Structure==
@@ Line 14: / Line 14: @@
 [[Category: Bacillus anthracis]]
 [[Category: Single protein]]
-[[Category: Liddington, R.C.]]
+[[Category: Liddington, R C.]]
-[[Category: Wong, T.Y.]]
+[[Category: Wong, T Y.]]
 [[Category: MFM]]
 [[Category: ZN]]
@@ Line 22: / Line 22: @@
 [[Category: zinc metalloproteinase]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jan 29 17:45:15 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:20:07 2008''